Inga Zerr

Detection of alpha synuclein seeding activity in tear fluid in patients with Parkinson's disease

This study detects alpha-synuclein seeding activity in tear fluid from Parkinson's disease patients using aSynSAA, showing higher activity in PD compared to controls and prion disease.

Tau oligomer heterogeneity and associated protein profile in slowly versus rapidly progressive Alzheimer's disease

This study compares Tau oligomer properties in slowly and rapidly progressive Alzheimer's disease, finding distinct biochemical and proteomic profiles associated with different clinical progression rates.

Proteomic and Kinetic Characterization of Prion Seeding in Distinct Human CJD Strains Unveils Early Diagnostic Biomarkers

The paper uses RT-QuIC and proteomics to analyze prion seeding activity and identify early diagnostic biomarkers in human CJD strains.

Molecular and structural remodeling of stress granules in slowly and rapidly progressive Alzheimer's disease

This study characterizes stress granule structural and molecular changes in Alzheimer's disease subtypes using multi-omics approaches, revealing distinct features in rapidly progressive AD.

Gpnmb Defines a Phagocytic State of Microglia Linked to Neuronal Loss in Prion Disease

The paper identifies Gpnmb as a marker of a phagocytic microglial state linked to neuronal loss in prion disease, showing its role in clearing apoptotic cells.

Genome wide association study of clinical duration and age at onset of sporadic CJD

This study identifies genetic variants associated with clinical duration in sporadic CJD but finds no significant SNPs for age at onset.

Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases

This study identifies ADAM10-mediated shedding of human PrP at Y226 and shows sPrP associates with misfolded protein aggregates in neurodegenerative diseases.

Ligands binding to the cellular prion protein induce its protective proteolytic release with therapeutic potential in neurodegenerative proteinopathies

The paper shows that ligands binding to PrPC induce its proteolytic release, which has neuroprotective effects, and identifies mechanisms and exceptions in this process.

Domain-specific quantification of prion protein in cerebrospinal fluid by targeted mass spectrometry

The paper develops a targeted mass spectrometry method to quantify prion protein in CSF, confirming that reduced PrP levels in prion disease are due to the disease process, not ELISA artifacts.

Age of onset in genetic prion disease and the design of preventive clinical trials

This paper quantifies the challenges of designing preventive clinical trials for genetic prion disease due to high variability in age of onset, suggesting the need for biomarker-based trials.

Prion protein quantification in cerebrospinal fluid as a tool for prion disease drug development

This study evaluates ELISA-based quantification of PrP in CSF as a biomarker for PrP-reducing therapeutics, showing its reliability and CNS origin.